Fig 3.
The C-terminal tail peptides of FGF19 and FGF21 are interchangeable in inhibiting the signaling of FGF19. (A) Immunoblot analysis of phosphorylation of FRS2α (pFRS2α) and 44/42 MAP kinase (p44/42 MAPK) in the rat hepatoma cell line H4IIE, which had been pretreated with FGF19C-tail and then stimulated with FGF19. As controls, cells were stimulated with FGF19 or FGF19C-tail alone. (B) Immunoblot analysis of phosphorylation of FRS2α (pFRS2α) and 44/42 MAP kinase (p44/42 MAPK) in the rat hepatoma cell line H4IIE, which had been pretreated with FGF21C-tail and then stimulated with FGF19. As controls, cells were stimulated with FGF19 or FGF21C-tail alone. Numbers above the lanes give the amounts of protein/peptide added in ng ml−1. To control for equal sample loading, the protein blots were probed with an antibody recognizing both phosphorylated and nonphosphorylated 44/42 MAP kinase (44/42 MAPK). The data shown in each figure panel are representative of two independent experiments.